Stemline Therapeutics (STML) Files $50M IPO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts STML Hot Sheet
Join SI Premium – FREE
In a Form S-1 late Monday, Stemline Therapeutics (Nasdaq: STML) registered a $50 million initial public offering. The company plans to list on the NASDAQ under the symbol "STML."
The offering is being made through Oppenheimer and JMP Securities.
Stemline is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.
The offering is being made through Oppenheimer and JMP Securities.
Stemline is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic files for Nasdaq IPO, reports $80.7B loss in first half
- City Therapeutics raises $230M in upsized Nasdaq IPO
- Actuate Therapeutics prices $11M public offering of stock and warrants
Create E-mail Alert Related Categories
IPOsRelated Entities
JMP Securities, S1Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
